Clinical Updates & Insights

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

Stay Informed
Get the latest information on MSK’s cancer treatments and research sent straight to your inbox with our monthly clinical updates e-newsletter OncoNotes.
Newsletter Sign Up
233 Clinical Updates found
Rectal Cancer Disappears After Experimental Use of Immunotherapy
Rectal Cancer Disappears After Experimental Use of Immunotherapy

Rectal cancer patients saw their tumors disappear in a clinical trial involving immunotherapy at Memorial Sloan Kettering Cancer Center—without surgery, radiation, or chemotherapy.
Trastuzumab Deruxtecan (T-DXd) for Treating HER2-Low Breast Cancer Shows Promise
Trastuzumab Deruxtecan (T-DXd) for Treating HER2-Low Breast Cancer Shows Promise

At the annual ASCO meeting, MSK medical oncologist Shanu Modi is presenting results from a clinical trial that found more people can benefit from a targeted therapy for breast cancer than previously thought.
Memorial Sloan Kettering Cancer Center Study Points to Expanded Genomic Testing that Aims To Benefit Children and Young Adults With Cancer

By sequencing the entire genome of a tumor, the experimental test will go beyond standard testing for common cancers in adults.
Dr. Nancy Y. Lee
MSK Finds De-escalation of Radiotherapy Safely Limits Side Effects for HPV-Associated Oropharyngeal Cancer

A study by Memorial Sloan Kettering (MSK) recently published in JAMA Oncology showed that radiation dose to the elective regions can be safely de-escalated for patients with human papillomavirus (HPV)-associated oropharyngeal cancer (OPC) who received concurrent chemotherapy.
Vinod Balachandran, MD
Custom mRNA Vaccines for Pancreatic Cancer

Cancer vaccines that use messenger RNA (mRNA) technology are an exciting new approach to develop immunotherapies for cancers with poor prognoses, such as pancreatic cancer.
MSK's team of experts discussing advanced therapies available to treat acute leukemia, myeloproliferative neoplasms, myelodysplastic syndromes, and chronic myeloid leukemia.
Promising Results in Phase 1 Study of Novel Menin Inhibitor for Aggressive Leukemia

The oral menin inhibitor SNDX-5613 (Syndax Pharmaceuticals) demonstrated promising antileukemic activity and an acceptable safety profile in patients w...
2021 in Review: 10 Important Clinical Advances in Cancer at MSK

MSK Chief of the Lymphoma Service Gilles Salles Presents Promising New Treatment for Patients with Diffuse Large B-Cell Lymphoma

Shape-Sensing Robotic-Assisted Bronchoscopy May Improve Diagnostic Efficiency, Shorten Time to Treatment for Patients with Malignant Lung Lesions

Updates 9/2/25: Dr. Bott, pathologist Marina Baine, MD, PhD, and interventional pulmonologist Or Kalchiem-Dekel, MD, recently led the first study to ev...
The timing and order of treatment modalities to address brain metastases is complex. MSK’s multidisciplinary brain metastasis experts create a customized treatment plan for each patient, ensuring multimodality treatments are delivered in the best order, as quickly as possible, for the greatest benefits.
Multimodality Care Is Improving Survival for Patients with Melanoma Brain Metastasis

Overall survival (OS) for patients with melanoma brain metastasis treated at Memorial Sloan Kettering Cancer Center has increased significantly over the past five years, up to 13 months, according to our research published recently in Cancer.